Exabis Library
Welcome to the e-CCO Library!
DOP39: The first prospective, mucticentre, randomised controlled trial on discontinuation of infliximab in Ulcerative Colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP39: The first prospective, mucticentre, randomised controlled trial on discontinuation of infliximab in Ulcerative Colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP39: Utilization and sustainability of biologics in UC - A nationwide study from the epi-IIRN
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP40 Does levels of concerns and expectations predict IBD disease status?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP40: Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn's disease treated with upadacitinib
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinib
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP40: Does levels of concerns and expectations predict IBD disease status?
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP40: Does levels of concerns and expectations predict IBD disease status?
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP40: Impact of corticosteroid usage on efficacy and safety outcomes in patients receiving upadacitinib for Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP40: Inflammatory Bowel Disease single cell atlas construction to enable cell type-specific target identification
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trial
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP41: Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studies
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM